A Step-By-Step Roadmap To Success

One-Stop Digital Agency

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Elit ullamcr dignissim cras tincidunt lobortis feugiat.

Clinical interventional Trials

The main purpose of this study is to identify whether so-called radioligands (small radioactive particles)can detect mutant Huntingtin (mHTT) in the brain.  This imaging study is done on humans and uses PET scans (images) of the brain to see if the presence of radioligands corresponds with the expression of mutant huntingtin in brain cells.  The objective of the study is to use PET scans of radioligands to measure the presence of mHTT in brain cells.  If proven valid and to be an effective way to measure mHTT, it can be used to measure if huntingtin lowering therapies actually lower mHTT in the brain.  This study is important and needs volunteers because we still don’t have any methods to measure whether the huntingtin lowering therapies actually gets into the brain tissue where it’s needed and whether the mHTT levels are lowered

 

Learn more

 

The main purpose of this study is to determine whether a drug called Neflamapimod can improve cognitive functions (planning, memory etc) in patients with early-stage HD. The drug is taken orally.  In the study 16 patients will receive the drug for 10 weeks and then be given placebo for 10 weeks or vice versa.  Neither the doctor nor the patient knows in which period they get the active drug or the placebo.  The effect will be tested with different cognitive tests.

Neflamapimod target an enzyme in the brain called p38 alpha. The aim is to reduce expression of the enzyme in neurons and enable the cells to function better.  The drug has proven promising effect in animal tests and it is also currently being tested on patients with Alzheimers Disease. 

Learn more

DOMINO-HD will focus on aspects of life for people with Huntington’s that haven’t been studied in depth up until now to improve quality of life for HD patients and families. The main purpose of this study is to look at how sleep, nutrition and physical activity impacts the progression of Huntington´s disease so as to develop new ways to support and manage fundamental aspects of HD patients. The study will also explore how digital technologies, such as wearable fitness trackers, can be used to support people with HD.

Learn more

he main objective of the study is to develop and validate an analytical and clinical Non-Invasive Prenatal Diagnosis (NIPD) test for triplet repeat diseases by isolated circulating fetal trophoblastic cells (CFTC) analysis from maternal blood, searching for the familial mutation in families at risk of having one of the following triplet repeat diseases: Huntington’s disease, Steinert Myotonic dystrophy, Fragile X syndrome, spinocerebellar ataxia (SCA) 1, 2 and 3.

Learn more 

 The main purpose of the study is to characterize the movement of the drug RO7234292 (RG6042) into, through, and out of the Cerebrospinal fluid( CSF)and plasma in addition to their reaction to the drug. The study will also look at the acute time course and recovery profile of CSF, mHHT lowering in response to RO7234292 (RG6042) treatment after intrathecal (IT) administration of RO7234292 (RG6042) to patients with manifest Huntington’s disease (HD).

Learn more

This is a phase III trial where HD patients get injections in the spine with a drug called Tominersen (previously called RG6042).  The drug is supposed to reduce the amount of Huntingtin in braincells. Some of the participants gets the active drug injected every 2nd months, another group gets the active drug every 4 months and a third group gets injected with the placebo. The potential effect of the study will be measured by testing cognitive, motor and social functioning. 

Learn more

 

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Ut elit tellus, luctus nec ullamcorper mattis, pulvinar dapibus leo.